RxDoctor Payments Data

Alan Chang, MD

Gastroenterology · Doylestown, PANPI 1912992330

Payments from drug & device makers

$49,610in general payments, 2019–2025

Across 676 payments — averaging $73.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$34K
  • Intercept Pharma Europe Ltd.$3K
  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$879
  • Johnson & Johnson$836
  • plus $7K from 43 others

What the payments were for

  • Consulting fees$130%
  • Food & beverage$12,86199%
  • Education$701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,610 in reported general payments places this provider in the 85th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$326,081
Medicare patients
673
Services billed
7,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab21$597,938
LinzessLinaclotide46$33,140
XifaxanRifaximin12$29,116
CreonLipase/Protease/Amylase11$28,389
Mesalamine DrMesalamine17$17,344
SutabSod Sulf/Pot Chloride/Mag Sulf99$15,806
Mesalamine37$10,295
Dexlansoprazole DrDexlansoprazole19$5,371
Omeprazole342$2,845
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C15$2,077
CholestyramineCholestyramine (With Sugar)26$1,782
Budesonide DrBudesonide15$1,768
Pantoprazole Sodium166$1,641
Famotidine153$1,248
Esomeprazole Magnesium35$1,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$836$597,93821 claims
AbbVieLinzess, Creon$2,751$61,52957 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$1,320$31,19327 claims
Braintree Laboratories, Inc.Sutab$272$15,80699 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →